Spherium Biomed has recently signed a licensing agreement with Simini Technologies from Ontario (Canada) to develop veterinarian applications based on the Spherium’s proprietary topical cyclosporine (SP14019).
Simini will develop its lead product, SMN-023, to treat atopic dermatitis in dogs, based on Spherium’s intellectual property. Under the terms of the agreement, Simini gains exclusive worldwide rights to develop and commercialise all veterinary products of the technology supporting SP14019, in exchange for development and commercial milestones and royalties.
ABG Patentes is proud to have collaborated with Spherium Biomed in the IP protection of SP14019 and other products in the company’s pipeline.
ABG is a leading European IP firm. ABG’s more than 60 professionals combine experience, outstanding technical knowledge and deep legal expertise to be at the forefront of IP law.
